Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (321-330 of 442) with videos related to

Pageof 45
Sort By:
AIDS (London, England)|December 17, 2009
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlJose R Arribas, Andrzej Horban, Jan Gerstoft, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
Plos One|August 4, 2011
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisSandra Mathis, Bettina Khanlari, Federico Pulido, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
HIV Clinical Trials|August 26, 2010
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trialsMark Nelson, Martin Fisher, Juan Gonzalez-Garcia, et al.
AIDS (London, England)|February 14, 2018
Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individualsBorja Mora-Peris, George Bouliotis, Kulasegaram Ranjababu, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite studyLucy Garvey, Mark Nelson, Ngaire Latch, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2012
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsMark Nelson, Gerardo Amaya, Nathan Clumeck, et al.
Journal of the International AIDS Society|November 14, 2014
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysisMarisa Montes, Mark Nelson, Pierre Marie Girard, et al.
Pageof 45

Showing results (321-330 of 442) with videos related to

Sort By:
Pageof 45
AIDS (London, England)|December 17, 2009
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlJose R Arribas, Andrzej Horban, Jan Gerstoft, et al.
Annals of Internal Medicine|August 17, 2005
A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapyMark Bower, Brian Gazzard, Sundhiya Mandalia, et al.
Plos One|August 4, 2011
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisSandra Mathis, Bettina Khanlari, Federico Pulido, et al.
AIDS (London, England)|June 3, 2009
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAnthony M Mills, Mark Nelson, Dushyantha Jayaweera, et al.
HIV Clinical Trials|August 26, 2010
Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trialsMark Nelson, Martin Fisher, Juan Gonzalez-Garcia, et al.
AIDS (London, England)|February 14, 2018
Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individualsBorja Mora-Peris, George Bouliotis, Kulasegaram Ranjababu, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite studyLucy Garvey, Mark Nelson, Ngaire Latch, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2012
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsMark Nelson, Gerardo Amaya, Nathan Clumeck, et al.
Journal of the International AIDS Society|November 14, 2014
Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysisMarisa Montes, Mark Nelson, Pierre Marie Girard, et al.
Pageof 45